Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis

Pharmaceutical Statistics

Volumn 8, Issue 3, 2009, Pages 225-238

  Ploeger, Berend Arnold ^a,b   Holford, Nicholas H G ^c  

^a LAP and P Consultants BV   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alzheimer's disease; Delayed start design; Disease progression modelling; Parkinson's disease; Statistical power; Washout design

Indexed keywords

DRUG; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; GENERAL CONDITION DETERIORATION; HUMAN; INTERMETHOD COMPARISON; PARKINSON DISEASE; PLACEBO EFFECT; POWER ANALYSIS; SAMPLE SIZE; SYMPTOMATOLOGY; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN; TIME FACTORS;

EID: 73349127010     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.355     Document Type: Article

References (36)

1. Chan PL, Holford NH. Drug treatment effects on disease progression. Annual Review of Pharmacology and Toxicology 2001; 41:625-659. DOI: 10.1146/annurev.pharmtox.41.1.625.
2. Clarke CE. Parkinson's disease. British Medical Journal 2007; 335(7617):441-445. DOI: 10.1136/bmj.39289.437454.AD.
3. Schapira AH. Progress in neuroprotection in Parkinson's disease. European Journal of Neurology 2008; 15(Suppl 1):5-13. DOI: 10.1111/j.1468-1331.2008.02055.x.
4. Clarke CE. A 'cure' for Parkinson's disease: can neuroprotection be proven with current trial designs? Movement Disorders 2004; 19(5):491-498. DOI: 10.1002/mds.20057.
5. Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimer's and Dementia 2006; 2(4):263-271.
6. Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I. Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments. Journal of Pharmacokinetics and Pharmacodynamics 2006; 33(3):281-311. DOI: 10.1007/s10928-006-9012-6.
7. Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Current Opinion in Neurology 2007; 20(4):477-483. DOI: 10.1097/WCO.0b013e32826388d6.
8. Knopman D. Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Alzheimer's and Dementia 2006; 2(3):147-149.
9. Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Statistics in Medicine 2004; 23(2):305-314. DOI: 10.1002/sim.1718.
10. Vellas B, Andrieu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurology 2007; 6(1):56-62. DOI: 10.1016/S1474-4422(06)70677-9.
11. Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clinical Trials 2005; 2(6):509-518.
12. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Archives of Neurology 2004; 61(4):561-566. DOI: 10.1001/archneur.61.4.561.
13. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? Journal of Neurology 2005; 252(Suppl 4):IV37-IV42. DOI: 10.1007/s00415-005-4008-5.
14. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Movement Disorders 2002; 17(5):961-968. DOI: 10.1002/mds.10226.
15. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharmaceutical Research 2007; 24(4):791-802. DOI: 10.1007/s11095-006-9202-3.
16. Aisen PS. Commentary on 'Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials'. Alzheimer's and Dementia 2006; 2(4):272-274.
17. Mohs RC, Kawas C, Carrillo MC. Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimer's and Dementia 2006; 2(3):131-139.
18. McDermott MP, Hall WJ, Oakes D, Eberly S. Design and analysis of two-period studies of potentially disease-modifying treatments. Controlled Clinical Trials 2002; 23(6):635-649.
19. Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Movement Disorders 2008; 23(6):784-789. DOI: 10.1002/mds.21918.
20. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. The New England Journal of Medicine 1993; 328(3):176-183.
21. Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annual Review of Pharmacology and Toxicology 2000; 40:209-234. DOI: 10.1146/annurev.pharmtox.40.1.209.
22. Bergamasco B, Frattola L, Muratorio A, Piccoli F, Mailland F, Parnetti L. Alpha-dihydroergocryptine in the treatment of de novo Parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurologica Scandinavica 2000; 101(6):372-380.
23. Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement Disorders 2007; 22(3):359-365. DOI: 10.1002/mds.21258.
24. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68(1):20-28. DOI: 10.1212/01.wnl.0000250355.28474.8e.
25. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Archives of Neurology 2002; 59(12):1937-1943.
26. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology 2002; 59(10):1541-1550.
27. Grosset K, Grosset D, Lees A. Trial of subtherapeutic pergolide in de novo Parkinson's disease. Movement Disorders 2005; 20(3):363-366. DOI: 10.1002/mds.20361.
28. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine 2004; 351(24):2498-2508. DOI: 10.1056/NEJMoa033447.
29. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Archives of Neurology 2003; 60(12):1721-1728. DOI: 10.1001/archneur.60.12.1721.
30. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68(4):272-276. DOI: 10.1212/01.wnl. 0000252355.79284.22.
31. Bhattaram VA, Siddiqu O, Gobburu J. Understanding Parkinson's disease: model-based approach. Available at: www.fda.gov/ohrms/dockets/ac/06/slides/2006- 4248s2-4-FDABhattaram&Siddiqui.ppt (last visited at 2008-04-27).
32. Duffull SB, Eccleston J, Kimko HC, Denman NG. WinPOPT User Guide [www.winpopt.com], University of Otago, Dunedin, New-Zealand, 2007.
33. Tukey JW. Exploratory Data Analysis. Addison-Wesley: Reading, MA, 1977.
34. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. Journal of Pharmacokinetics and Pharmacodynamics 2001; 28(3):231-252.
35. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. Journal of Pharmacokinetics and Pharmacodynamics 2003; 30(1):83-103.
36. Little RJA, Rubin DB: Statistical Analysis with Missing Data. Wiley: New York, 1987.